Abstracts

  • October 21-24, 2018
    Henry B. Gonzalez Convention Center
    San Antonio, TX

    Abstract submission site is now CLOSED! 

    If you have any questions regarding your submission please contact the Annual Meeting team.

    Notifications: Notifications will be sent to the submitting author by Friday, April 27, 2018.

    Late-breaking Abstract Submission Site Opens: July 18, 2018
    Late-breaking Abstract Submission Site Closes: August 1, 2018 at 11:59 p.m. Pacific time 

    NEW! Electronic Poster Viewing Session Format

    New for 2018, all poster viewing presentations will be displayed as electronic posters! Posters will be integrated into the Exhibit Hall in a new and exciting floorplan that will offer large, touchscreen monitors and an interactive format for all poster presenters. No more paper posters, tubes or poster printing!

    The electronic format will allow for:

    • Scheduled presentation times for each author in order to foster networking and improved visibility of individual posters, similar to Poster Q&A in 2017.
    • Integration of posters into Exhibit Hall; no separate poster hall.
    • Utilization of new technology to build better posters; including video and other graphics.
    • Elimination of paper posters, traveling with poster tube and poster waste. A nominal fee of $60 will be assessed for digital upload.
    • “Posters on Demand” feature, to search and view all posters at stations in the Exhibit Hall, on the mobile app and the Online Conference Planner, during and after the meeting. 

    Program Description

    ASTRO’S Annual Meeting is the premier radiation oncology scientific event in the world and draws more than 11,000 attendees each year. During the 2018 Annual Meeting we will showcase the unique ability of radiation to cure cancer. We will emphasize new scientific discoveries and how to translate these new findings into clinical applications, and opportunities for cure. The meeting program will continue to spotlight the importance of palliation and supportive care.

    The scientific program is the ideal platform to bring together clinicians, scientists and researchers from all oncology disciplines to exchange ideas, promote multidisciplinary care and address the educational and professional development interests of our attendees. Scientific and educational sessions will cover specific clinical areas including breast, central nervous system, gastrointestinal, genitourinary, gynecologic, head and neck, immunotherapy, lymphoma, musculoskeletal, pediatric, sarcoma and thoracic cancers.

    Radiation biology and radiation physics concepts will be explored in their own tracks. The Annual Meeting will feature a continued emphasis on patient quality and safety issues in the delivery of radiation therapy in the areas of treatment techniques, equipment, terminology and professional responsibilities. Program content has been designed to address specific, documented and clinically important practice gaps in physician knowledge, competence and performance.

    Abstract Scoring Criteria

    Abstracts will be scored by blind peer review based on the following criteria:

    • Does the abstract address an important and novel question?
    • Does the study design permit the question to be answered?
    • Are the endpoints of the study clearly defined?
    • Is there an appropriate use of statistics?
    • Are the methods described in sufficient detail?
    • Are the conclusions supported by the data?

    Specific questions for prospective Clinical Trials: 

    • What were the scientific hypothesis and primary endpoint?
    • What were the eligibility criteria and study patient characteristics?
    • What statistical model and assumptions were used?
    • What was the toxicity assessment?
    • What were the limitations?
    • Was there a rationale, either clinical or laboratory, underlying the study design? 
    • Is it either promising enough to pursue or negative enough that presentation would prevent other investigators from wasting efforts? 

    Specific questions for retrospective observational studies:

    • What are the scientific hypothesis and outcomes reported?
    • What is the data source and how was follow-up attained?
    • Is the cohort well described and reasonably homogeneous? 
    • Have attempts been made to account for biases inherent in retrospective reviews?
    • What statistical methods were used?
    • Are the conclusions appropriate to the study design?

    Disclosure Policy

    ASTRO is an accredited provider of continuing medical education and adheres to the policies and standards set forth by the Accreditation Council for Continuing Medical Education (ACCME). As such, abstract authors are required to disclose relationships with commercial interests. A commercial interest is defined as "any entity developing, producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients."

    To ensure its compliance, ASTRO expects that the content and related materials will promote improvements or quality in health care and not a specific proprietary business interest or commercial bias. 

    We employ several strategies to ensure absence of bias:

    • Presenters are required to provide disclosure of relationships with commercial interests.
    • Presenters are required to provide a balanced view of therapeutic options.
    • All abstracts undergo a rigorous peer review process.
    • Potential conflicts are managed by additional committee review, advance slide review and session audits.

    Embargo Policy and ASTRO Press Policy

    All abstracts submitted to the ASTRO Annual Meeting are embargoed until the date and time of presentation unless otherwise noted by ASTRO. The submitting author is responsible for conveying this information to all co-authors. All abstracts accepted for presentation at the ASTRO Annual Meeting may be highlighted in ASTRO’s Press Program. All submitters agree to cooperate in the publicity of their study. For questions regarding the embargo or press policy, please contact ASTRO’s Media Relations Team.